MetaCap

Benitec Biopharma (BNTC) vs Vicore Pharma AB (VCRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Benitec Biopharma is the larger company by market cap ($285.9 million vs $264.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BNTC-40.04%VCRE-42.12%
+7%-21%-49%
Jul 6, 20261 yearNov 20, 2026
BNTC-41.02%VCRE-31.75%
+4%-20%-43%
Jul 6, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BNTC versus VCRE key metrics
MetricBNTCVCRE
Share price$7.92$9.41
Market cap$285.88M$264.89M
1-day change-2.76%-5.09%
YTD return-41.24%—
1-year return-40.31%—
5-year return-85.67%—
EPS (TTM)$-1.02$-2.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-45.55M—
52-week high$14.39$17.80
52-week low$7.72$7.88
Distance from 52-week high-45.00%-47.16%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+200.06%+158.90%
Average volume174.01K23.31K
Shares outstanding36.12M28.16M
Employees2450
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Benitec Biopharma

BNTC stock →

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.

Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees

About Vicore Pharma AB

VCRE stock →

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 50 employees

BNTC vs VCRE FAQ

Which is bigger, Benitec Biopharma or Vicore Pharma AB?

Benitec Biopharma (BNTC) is larger, with a market capitalization of $285.88M compared with $264.89M for Vicore Pharma AB (VCRE).

Are Benitec Biopharma and Vicore Pharma AB in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons